Neurocrine Biosciences (NBIX) Enterprise Value (2010 - 2026)

Neurocrine Biosciences has reported Enterprise Value for 17 years, with the latest figure at -$1.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value fell 39.5% year-over-year to -$1.3 billion; the trailing twelve-month figure through Mar 2026 stood at -$1.3 billion (down 39.5% YoY), and the FY2025 full-year result was -$1.5 billion, down 37.57% from the prior year.
• Enterprise Value for Q1 2026 stood at -$1.3 billion, up from -$1.5 billion in the prior quarter.
• The five-year high for Enterprise Value was -$648.3 million in Q2 2022, with the low at -$1.5 billion in Q4 2025.
• Historically, Enterprise Value has averaged -$1.0 billion across 5 years, with a median of -$1.0 billion in 2024.
• Annual changes were most pronounced in 2022 — Enterprise Value rose 26.74% — and 2023, when it slumped 50.66%.
• Neurocrine Biosciences' Enterprise Value stood at -$997.1 million in 2022, then dropped by 4.26% to -$1.0 billion in 2023, then retreated by 3.51% to -$1.1 billion in 2024, then sank by 37.57% to -$1.5 billion in 2025, then climbed by 11.09% to -$1.3 billion in 2026.
• The last three Enterprise Value figures came in at -$1.3 billion (Q1 2026), -$1.5 billion (Q4 2025), and -$1.1 billion (Q3 2025), per Business Quant data.